Rigel Pharmaceuticals RIGL Single reportable segment — Outside clinical trial related expenses

Similar metrics at other companies

IBRXReportable Segment — External research and development expense (including amounts with related parties)

$20.08M+264%

INBXReportable Segment — Research And Development Expense, Clinical Trials

$9.18M-30.8%

SIONReportable Segment — External research and development expense

$12.93M+29.6%

BCAXReportable Segment — Clinical operations and development

$23.21M+24.4%

AVTXReportable Segment — Nonclinical expenses

$419K+405%

INCYReportable Segment — Research and development - external

$243.13M+25.7%

Other financials

Income statement

See full

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Balance sheet

See full

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Cash flow

See full

Operating cash flow$2.7M+405%

CapEx$73.0K—

Free cash flow-$22.0M—

Valuation

See full

Market cap$684.39M+102%

Enterprise value$728.29M+148%

P/E1.9×-7.2×

P/S2.3×+0.6×

Profitability

See full

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

FCF margin-61.7%—

Returns & leverage

See full

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept rigl:OutsideClinicalTrialRelatedExpenses.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's single reportable segment — outside clinical trial related expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rigel Pharmaceuticals's single reportable segment — outside clinical trial related expenses?: Rigel Pharmaceuticals (RIGL) reported single reportable segment — outside clinical trial related expenses of $6.93M in Q1 2026.
What does single reportable segment — outside clinical trial related expenses mean?: Reflects the costs associated with outsourced clinical research, trial management, and external medical studies. These expenses are critical for evaluating the company's R&D pipeline progression and the intensity of its clinical development efforts.